SCHEMBL23880060

SCHEMBL23880060

CC(C)(C)c1ccc(C(=O)N2CC(O)C2)nc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 10/20 0.46
▸ SCN10A Q9Y5Y9 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ RBP4 P02753 1/20 0.43
▸ PLA2G1B P04054 1/20 0.42
▸ ATG4B Q9Y4P1 1/20 0.42
▸ PDE10A Q9Y233 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ PDK1 Q15118 1/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL3 Q96JM7 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23880061 0.89 SCN9A (0.49) SCN9AALDH1A1PLA2G1BATG4BSMN1; SMN2
SCHEMBL25972074 0.88 ALDH1A1 (0.45) SCN9AALDH1A1RBP4PLA2G1BATG4B
SCHEMBL23880056 0.86 ALDH1A1 (0.48) SCN9AALDH1A1RBP4PLA2G1BATG4B
SCHEMBL23880057 0.86 SCN9A (0.47) SCN9AALDH1A1RBP4PLA2G1BATG4B
SCHEMBL25972071 0.83 ALDH1A1 (0.47) SCN9AALDH1A1RBP4PLA2G1BATG4B
SCHEMBL25972070 0.81 ALDH1A1 (0.49) SCN9ASCN10AALDH1A1RBP4PLA2G1B
SCHEMBL13467096 0.80 PDE10A (0.56) SCN9ASCN10ARBP4PDE10ASMN1; SMN2
SCHEMBL25972082 0.80 HPGD (0.50) ALDH1A1RBP4PLA2G1BATG4BSMN1; SMN2
SCHEMBL2733495 0.78 SMN1; SMN2 (0.65) SCN9AALDH1A1SMN1; SMN2MEN1HTT
SCHEMBL20254512 0.77 SMN1; SMN2 (0.41) SCN9ASCN10ARBP4PDE10ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-03-31 — — US disclosed
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2021-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS PIK3CD, PIK3R5, PIK3CA SCN9A 718/4885SCN10A 915/4885ALDH1A1 1902/4885
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors PIK3CD, PIK3R5, PIK3CA SCN9A 999/4885SCN10A 1072/4885ALDH1A1 1964/4885
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors PIK3CD, PIK3R5, PIK3CA SCN9A 951/4885SCN10A 1072/4885ALDH1A1 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback